Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 18-75 years of age (inclusive), male or female, at the time of informed consent~* Moderate to severe atopic dermatitis~* Capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspect of the study~Exclusion Criteria:~* Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study~* Subject has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of atopic dermatitis~* Subject has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active Comparator: SHR0302 dose A (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
- Active Comparator: SHR0302 dose B (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
- Placebo Comparator: Placebo (Type: ACTIVE_COMPARATOR): Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).